Nektar Therapeutics (NASDAQ:NKTR) COO John Nicholson Sells 3,819 Shares

Nektar Therapeutics (NASDAQ:NKTR) COO John Nicholson sold 3,819 shares of the business’s stock in a transaction that occurred on Friday, August 16th. The stock was sold at an average price of $18.15, for a total value of $69,314.85. Following the transaction, the chief operating officer now directly owns 162,759 shares in the company, valued at approximately $2,954,075.85. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Shares of NKTR stock traded down $0.23 during trading on Monday, reaching $17.87. 3,641,868 shares of the company’s stock were exchanged, compared to its average volume of 1,921,491. The company has a quick ratio of 14.83, a current ratio of 14.09 and a debt-to-equity ratio of 0.22. The firm’s fifty day moving average price is $29.37 and its 200-day moving average price is $33.95. Nektar Therapeutics has a twelve month low of $17.30 and a twelve month high of $69.76. The stock has a market capitalization of $3.19 billion, a PE ratio of 4.73 and a beta of 2.67.

Nektar Therapeutics (NASDAQ:NKTR) last issued its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.63) EPS for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.17. Nektar Therapeutics had a negative return on equity of 25.25% and a negative net margin of 354.90%. The firm had revenue of $23.32 million for the quarter, compared to analyst estimates of $26.65 million. During the same period in the prior year, the firm posted $5.33 EPS. The company’s revenue for the quarter was down 97.9% on a year-over-year basis. As a group, analysts anticipate that Nektar Therapeutics will post -2.93 EPS for the current fiscal year.



NKTR has been the topic of a number of recent analyst reports. Zacks Investment Research lowered Nektar Therapeutics from a “buy” rating to a “hold” rating and set a $34.00 target price on the stock. in a report on Wednesday, July 31st. HC Wainwright reissued a “hold” rating on shares of Nektar Therapeutics in a report on Tuesday, August 13th. BMO Capital Markets decreased their target price on Nektar Therapeutics from $75.00 to $41.00 and set an “outperform” rating on the stock in a report on Friday, August 9th. Jefferies Financial Group lowered Nektar Therapeutics from a “buy” rating to a “hold” rating and decreased their target price for the stock from $59.00 to $23.00 in a report on Friday, August 9th. Finally, JPMorgan Chase & Co. lowered Nektar Therapeutics from an “overweight” rating to a “neutral” rating and decreased their target price for the stock from $62.00 to $33.00 in a report on Friday, August 9th. One analyst has rated the stock with a sell rating, eight have given a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $49.15.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Invesco Ltd. grew its holdings in Nektar Therapeutics by 1,057.7% in the 2nd quarter. Invesco Ltd. now owns 23,343,019 shares of the biopharmaceutical company’s stock valued at $830,544,000 after buying an additional 21,326,731 shares in the last quarter. Vanguard Group Inc. grew its holdings in Nektar Therapeutics by 2.0% in the 2nd quarter. Vanguard Group Inc. now owns 18,512,772 shares of the biopharmaceutical company’s stock valued at $658,684,000 after buying an additional 356,193 shares in the last quarter. BlackRock Inc. grew its holdings in Nektar Therapeutics by 6.0% in the 2nd quarter. BlackRock Inc. now owns 13,264,987 shares of the biopharmaceutical company’s stock valued at $471,969,000 after buying an additional 749,644 shares in the last quarter. First Trust Advisors LP grew its holdings in Nektar Therapeutics by 39.9% in the 2nd quarter. First Trust Advisors LP now owns 3,005,999 shares of the biopharmaceutical company’s stock valued at $106,953,000 after buying an additional 856,819 shares in the last quarter. Finally, Camber Capital Management LP lifted its position in shares of Nektar Therapeutics by 25.0% during the 2nd quarter. Camber Capital Management LP now owns 2,500,000 shares of the biopharmaceutical company’s stock valued at $88,950,000 after acquiring an additional 500,000 shares during the period. 91.23% of the stock is currently owned by hedge funds and other institutional investors.

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company develops NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and NKTR-214, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I to treat immuno-oncology.

Featured Story: How are Outstanding Shares Different from Authorized Shares?

Insider Buying and Selling by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.